BioMarin Pharmaceuticals BMRN Accounts payable and accrued liabilities related to intangible assets
Accounts payable and accrued liabilities related to intangible assets at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept bmrn:CapitalExpendituresIncurredButNotYetPaidIntangibleAssets.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accounts payable and accrued liabilities related to intangible assets?
- BioMarin Pharmaceuticals (BMRN) reported accounts payable and accrued liabilities related to intangible assets of $4.48M in Q1 2026.
- What does accounts payable and accrued liabilities related to intangible assets mean?
- Capital investments in intangible assets that have been committed to but not yet paid for in cash.
- How do you interpret accounts payable and accrued liabilities related to intangible assets?
- An increase indicates ongoing investment in intangible assets that will impact future cash liquidity.
- How does accounts payable and accrued liabilities related to intangible assets compare across companies?
- Frequently seen in technology and pharmaceutical sectors where intangible asset development is a core strategy.